An optimized Lentiviral vector production platform for Yposkesi
Home > Stimulating sector development > Innovative therapies > An optimized Lentiviral vector production platform for Yposkesi
On 11 May, Minister of the Economy, Finance, Industrial and Digital Sovereignty Bruno Le Maire and Minister Delegate for Industry Roland Lescure inaugurated the Yposkesi site extension at Corbeil-Essonnes.
A specialist in the clinical and commercial production of viral vectors for gene & cell therapies, Yposkesi has deployed an optimized platform for the production of lentiviral vectors (LVs), which are the most widely used type in immuno-oncology.
The platform’s scalable, high-yield, high-quality process brings clear advantages to clients, notably as concerns CAR T-cell therapies. Indeed, their LentiSure system is able to provide constant yields of premium-grade LVs. Yposkesi thus positions itself as a leading and competitive actor in Europe for the bioproduction of viral vectors in France.
The optimized LV platform is the result of a long effort in bioprocesses innovation. It responds to a need for the production of cellular immunotherapies for cancer, a driver of the gene & cell therapies market, notably via the development of CAR T-cell therapies.
The new 5,000m² facility is now operational and has doubled Yposkesi’s cGMP production capacity for gene & cell therapies vectors.
